Fisher Asset Management LLC Has $6.75 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Fisher Asset Management LLC trimmed its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 10.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 185,756 shares of the biopharmaceutical company’s stock after selling 21,999 shares during the period. Fisher Asset Management LLC owned about 0.19% of Ultragenyx Pharmaceutical worth $6,754,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Parallel Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 669 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at about $55,000. Headlands Technologies LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $59,000. Covestor Ltd increased its stake in Ultragenyx Pharmaceutical by 86.8% in the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 795 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Ultragenyx Pharmaceutical by 231.4% in the first quarter. PNC Financial Services Group Inc. now owns 2,737 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 1,911 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $36.54 on Friday. The stock has a market cap of $3.53 billion, a PE ratio of -6.15 and a beta of 0.16. The stock has a 50-day moving average of $32.74 and a 200-day moving average of $32.42. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $50.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The business had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. During the same period in the previous year, the firm posted ($1.40) earnings per share. The firm’s revenue was up 14.6% on a year-over-year basis. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

RARE has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Canaccord Genuity Group lowered their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Finally, Wells Fargo & Company began coverage on shares of Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They set an “overweight” rating and a $65.00 price objective on the stock. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $80.23.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the firm’s stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at $3,095,132.77. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the transaction, the executive vice president owned 73,271 shares in the company, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,456 shares of company stock worth $328,486 in the last 90 days. Company insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.